Unique Wealth LLC Takes $1.03 Million Position in Johnson & Johnson (NYSE:JNJ)

Posted by on Apr 11th, 2023

Unique Wealth LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 5,852 shares of the company’s stock, valued at approximately $1,034,000. Johnson & Johnson comprises 0.6% of Unique Wealth LLC’s investment portfolio, making the stock its 20th biggest position.

A number of other hedge funds have also recently added to or reduced their stakes in JNJ. Glassy Mountain Advisors Inc. bought a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $35,000. Retirement Financial Solutions LLC bought a new position in Johnson & Johnson during the 4th quarter worth $40,000. TD Capital Management LLC acquired a new stake in Johnson & Johnson in the third quarter worth $48,000. Iron Horse Wealth Management LLC lifted its stake in Johnson & Johnson by 112.8% in the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after buying an additional 159 shares during the last quarter. Finally, Cowa LLC acquired a new position in shares of Johnson & Johnson during the third quarter valued at $58,000. Institutional investors and hedge funds own 67.94% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of analyst reports. Piper Sandler reduced their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Citigroup raised their target price on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. SVB Leerink reduced their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Morgan Stanley lowered their price target on Johnson & Johnson from $180.00 to $179.00 in a report on Monday. Finally, Atlantic Securities upped their price objective on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a report on Wednesday, January 25th. Eight research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $173.60.

Insider Buying and Selling

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.20% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Down 0.5 %

JNJ stock opened at $164.32 on Tuesday. The firm has a market cap of $427.94 billion, a PE ratio of 24.38, a P/E/G ratio of 2.85 and a beta of 0.53. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $186.69. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. The firm has a 50 day simple moving average of $157.42 and a 200 day simple moving average of $167.05.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. The company had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The company’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.13 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Recommended Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.